ArticleScientific reports2022
Burden of polycystic ovary syndrome in the Middle East and North Africa region, 1990-2019.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07399535 (Clinical Investigation of Herbal Formulation and Its Efficacy in Polycystic Ovarian Syndrome), which is not on this map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Investigation of Herbal Formulation and Its Efficacy in Polycystic Ovarian Syndrome
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Polycystic Ovary Syndrome prevalence and associated sociodemographic risk factors: a study among young adults in Delhi NCR, India.Reproductive health · 2025Pooled it
- Global prevalence of polycystic ovary syndrome in women worldwide: a comprehensive systematic review and meta-analysis.Archives of gynecology and obstetrics · 2024Pooled it
- Competence of Combined Low Dose of Human Chorionic Gonadotropin (HCG) and Clomiphene Citrate (CC) Versus Continued CC during Ovulation Induction in Women with CC-Resistant Polycystic Ovarian Syndrome: A Randomized Controlled Trial.Medicina (Kaunas, Lithuania) · 2024Trial
- Molecular analysis of FSHR rs6166 polymorphism and oxidative stress parameters in women with polycystic ovary syndrome.Molecular biology reports · 2026Article
- Prevalence and Clinical Features of Polyendocrine Metabolic Ovarian Syndrome in the Gulf Cooperation Council Countries: A Systematic Review and Meta-Analysis.Healthcare (Basel, Switzerland) · 2026Review
- Beyond weight loss: toward phenotype-guided, regionally calibrated interventions in polycystic ovary syndrome (PCOS).Medical review (2021) · 2026Article
- Global, Regional, and National Burden of Adolescent Polycystic Ovary Syndrome from 1990 to 2021, with Projections of Disease Burden to 2041: A Systematic Analysis Based on the Global Burden of Disease Study 2021.International journal of women's health · 2026Article
- Global, Regional, and National Burden of Endometriosis, PCOS, and Unexplained Infertility and Their Attribution to Infertility, 1990-2021: Global Burden of Disease Study 2021.Journal of evidence-based medicine · 2025Article
- Polycystic ovarian syndrome a risk factor for non-communicable diseases: insights into recent research and prevention approaches.Journal of ovarian research · 2025Review
- Association of vitamin D with depression and anxiety in polycystic ovary syndrome in Saudi Arabia.Journal of family medicine and primary care · 2025Article
- Decreased Sirtuin1 Protein and Aromatase Activity Index in Follicular Fluid is Correlated with Increased Germinal Vesicle Count in Polycystic Ovary Syndrome.Chonnam medical journal · 2025Article
- Mobile Apps Designed for Patients With Polycystic Ovary Syndrome: Content Analysis Using the Mobile App Rating Scale.Journal of medical Internet research · 2025Article
- Polycystic ovarian syndrome awareness among females in Palestine: a cross‑sectional study.Annals of medicine and surgery (2012) · 2025Article
- Assessment of Health-Related Quality of Life and the Role of Social Support in Reducing the Severity of Symptoms in Women with Polycystic Ovary Syndrome.Journal of obstetrics and gynaecology of India · 2025Article
- Effect of Junk Food on Hormonal and Metabolic Manifestations in Polycystic Ovarian Syndrome Phenotypes: A Case-Control Study of Kashmiri Population.Indian journal of clinical biochemistry : IJCB · 2025Article
- Article
- Prevalence and genetic etiology of poly-cystic ovarian syndrome (PCOS) in Mauritania.Frontiers in reproductive health · 2025Article
- The Global Burden of Polycystic Ovary Syndrome in Women of Reproductive Age: Findings from the GBD 2019 Study.International journal of women's health · 2025Article
- Role of epiregulin levels in polycystic ovary syndrome patients: new findings and clinical significance.Revista da Associacao Medica Brasileira (1992) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is one of the most important contributing factors to infertility. In this study, we report the burden of PCOS by age and sociodemographic index (SDI) for the 21 countries in the Middle East and North Africa (MENA) region. Publicly available data on the point prevalence, incidence and years lived with disability (YLDs), from 1990 to 2019, were retrieved from the Global Burden of Disease (GBD) 2019 study for the 21 countries in MENA. The results are presented with age-standardised numbers and rates per 100,000 population, along with their corresponding 95% uncertainty intervals (UIs). In 2019, the age-standardised point prevalence and incidence rate for PCOS in the MENA region were 2079.7 (95% UI: 1392.0 to 2812.3) and 77.2 (95% UI: 51.6 to 105.4) per 100,000, respectively, which represents a 37.9% (95% UI: 31.7 to 45.0) and a 33.7% (95% UI: 27.7 to 40.3) increase since 1990, respectively. Also in 2019, the age-standardised YLD rate of PCOS in this region was 18.7 (95% UI: 7.8 to 37.9) per 100,000 women, which has increased by 36.1% (95% UI: 29.4 to 43.4) since 1990. Kuwait [25.4 (10.7, 51.2)] had the highest age-standardised YLD rate, while Afghanistan [10.8 (10.1, 49.2)] had the lowest. Moreover, the largest increase in the YLD rate, from 1990 to 2019, was seen in Sudan [90.3% (64.1, 120.9)], whereas no country decreased during the measurement period. The total prevalent number and point prevalence of PCOS (per 100,000) were both highest in the 20-24 age group. The prevalence of PCOS was highest among women of reproductive age, but decreased rapidly after 45 years of age. Moreover, at the country level there was a positive association between SDI and the age-standardised YLD rates of PCOS. The growing prevalence and burden of PCOS in the MENA region highlights the need to implement cost-effective preventive programs, especially for women in their third decade of life, and in MENA countries with higher SDI levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.